TEST CHANGE

Felbamate

0094030, FELBAMA

Specimen Requirements:	
Patient Preparation:	Timing of specimen collection: Pre-dose (trough) draw - At steady state concentration.
Collect:	Plain red. Also acceptable: Lavender (EDTA), pink (K2EDTA), green (sodium heparin), gray (sodium fluoride/potassium oxalate). Avoid use of separator tubes and gels.
Specimen Preparation:	Transfer 1 mL serum or plasma to an ARUP Standard Transport Tube. (Min: 0.5 mL)
Transport Temperature:	Refrigerated.
Unacceptable Conditions:	
Remarks:	
Stability:	After separation from cells: Ambient: 72~~48~~ hours; Refrigerated: 2 weeks~~1 month~~; Frozen: 2 weeks~~6 months~~
Methodology:	Quantitative Liquid Chromatography-Tandem Mass Spectrometry
Performed:	Mon-Fri
Reported:	1-7~~4~~ days
Note:	
CPT Codes:	80167
New York DOH Approval Status:	This test is New York DOH approved.

Interpretive Data:

Felbamate is indicated for treatment of epilepsy. The therapeutic range is based on serum, predose (trough) draw collection at steady-state concentration. Patient pharmacokinetics may be variable due to age, co-medications, and/or compromised renal function. Adverse effects may include nausea, vomiting, dizziness, blurred vision and ataxia. Felbamate use may increase the incidence of liver failure and aplastic anemia.

This test was developed and its performance characteristics determined by ARUP Laboratories. It has not been cleared or approved by the US Food and Drug Administration. This test was performed in a CLIA certified laboratory and is intended for clinical purposes.

Reference Interval:

Effective November 15, 2021

Therapeutic Range	30-60 ug/mL
Toxic Level	Greater than or equal to 100 ug/mL